This blog draws on insights from Frost & Sullivan’s recent analyses, including “Global Clinical Diagnostics Outlook, 2025,” by Amartya Bose, Senior Consultant; “Global Pharmaceutical Industry Outlook, 2025,” by Aarti Siddhesh Chitale, Industry Principal; “Global Medical Devices Outlook, 2025,” by Vittal Bhaskar Rao, Research Manager; and “Global Medical Imaging Market Outlook, 2025,” authored by Anantharaman Viswanathan, Research Director, all from the Healthcare & Life Sciences Practice.
The healthcare industry is at a defining crossroads in 2025. Rapid advancements in diagnostics, therapeutics, devices, and imaging are reshaping the way care is delivered and competition is intensifying.
Frost & Sullivan’s Mid-Year 2025 Checkpoint Whitepaper offers an evidence-based view into the trends that will define the remainder of 2025 and set the tone for 2026 strategic planning.
If you are a leader in clinical diagnostics, pharmaceuticals, medical devices, or medical imaging, this is your blueprint for staying ahead in a rapidly evolving market.
The Mid-Year 2025 Checkpoint Whitepaper is designed as both a decision-making tool for the next six months and a strategic framework for 2026 planning.
Download the Whitepaper and Start Planning for 2026
Why Mid-2025 Is a Strategic Inflection Point
The second half of 2025 isn’t just “more of the same.” It’s a strategic pivot window, a period where organizations can adjust course based on real-world market shifts. The whitepaper delivers sector-by-sector intelligence to help decision-makers:
- Pinpoint growth segments and innovation hotspots
- Align investments with emerging healthcare delivery models
- Anticipate regulatory, supply chain, and technology shifts
- Build a resilient strategy for 2026 and beyond
Key Insights Across Four Sectors
- Clinical Diagnostics: Decentralization and Precision Take Center Stage
The global clinical diagnostics market is on track to hit $110.66 billion in 2025 (4.5% YoY growth). Three forces are driving this acceleration:
- Decentralized Testing: From point-of-care platforms to at-home testing kits, consumer empowerment is redefining diagnostics.
- AI & Automation: Faster, more accurate diagnostics via AI-powered pathology and integrated lab systems.
- Molecular Advances: Liquid biopsy and biomarker testing are making early, non-invasive cancer detection a reality.
Strategic takeaway: Organizations that integrate cloud-based LIMS and invest in companion diagnostics beyond oncology will secure competitive advantage.
Is your diagnostics strategy aligned with the rise of AI-enabled, at-home testing models? Could molecular diagnostics open new market share opportunities for your business?
- Pharmaceuticals: AI and New Therapies Reshape R&D
With the market projected to grow at 7.1% CAGR through 2030, pharmaceutical companies are entering a phase of therapeutic diversification and AI-enabled efficiency.
- GLP-1 Inhibitors Boom: Products like Ozempic, Mounjaro, and emerging entrants are projected to exceed $70 billion in sales in 2025.
- M&A Resurgence: $18 billion+ in deals in early 2025 alone signal renewed consolidation and innovation acceleration.
- AI in Clinical Trials: Nearly half of all trials now use AI for recruitment, monitoring, and protocol design.
Strategic takeaway: Future-ready pharma organizations are localizing supply chains and exploring radioligand therapies to diversify revenue streams.
Are you leveraging AI to reduce clinical trial timelines and costs? Could radioligand therapies or GLP-1 innovation disrupt your long-term portfolio plans?
- Medical Devices: Personalization Meets Robotics
The medical devices market is forecast to grow from $545 billion in 2024 to $801 billion in 2029, fueled by:
- Clinical-grade Wearables: Enabling continuous monitoring for stroke, respiratory care, and wound healing.
- Robotic Surgery Expansion: Telesurgery breakthroughs are extending specialist care to remote regions.
- China’s VBP Policy: Driving cost efficiencies while opening volume growth opportunities.
Strategic takeaway: Device makers must combine hardware, AI, and ecosystem-based care platforms to deliver long-term value.
Is your product roadmap ready for the next wave of telesurgery and personalized wearables? How will shifts in China’s procurement policies affect your device pricing strategy?
- Medical Imaging: AI Orchestration and Sustainability
Imaging is no longer just about clearer pictures—it’s about intelligent workflows and sustainable operations.
- AI Workflow Integration: Reducing radiologist burnout and improving diagnostic precision.
- Radiopharmaceutical Advances: Expanding PET/CT access for cardiovascular and cancer diagnostics.
- Helium-free MRI: Lower costs, reduced environmental impact, and easier installation.
Strategic takeaway: The future belongs to imaging leaders who marry AI with green innovation while expanding into mobile and decentralized care.
Are your imaging investments balancing AI integration with sustainability goals? Could mobile imaging expand your market reach into underserved regions?
The Second-half 2025 Outlook
Across all four sectors, common themes are emerging:
- Precision at Scale: Personalized medicine and targeted interventions are becoming standard.
- Decentralization of Care: From diagnostics to imaging, services are moving closer to the patient.
- AI Integration: Not as a buzzword, but as a measurable driver of accuracy, efficiency, and ROI.
- Resilience through Localization: Supply chain and regulatory strategies are becoming more regionalized.
Organizations that act now, adjusting strategy for the second half of 2025, will be better positioned to dominate 2026.
Putting the Mid-year Checkpoint to Work
The Mid-Year 2025 Checkpoint Whitepaper is designed as both a decision-making tool for the next six months and a strategic framework for 2026 planning. Inside, you’ll find:
- Market forecasts and data-backed projections for each sector
- Emerging technology adoption curves and competitive benchmarks
- Strategic questions to challenge your team’s assumptions
- Investment priorities for sustainable growth
📩 Download the Whitepaper and Start Planning for 2026
Final Thought
2025 is not just another year, it’s the launchpad for the next era of healthcare. Whether your focus is on diagnostics, drugs, devices, or imaging, the choices you make in the next six months will define your relevance in 2026. The question isn’t if healthcare will transform, it’s whether you will be the one leading that transformation.
